GeoVax to Sponsor the 2025 Dr. David Satcher Global Health Equity SummitSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Sponsor the 2025 Dr. David Satcher Global Health Equity SummitCompany Underscores Its Commitment to Advancing Equitable Access to Vaccines and Health Innovation on a Global Stage
GeoVax Labs Announces $2.5 Million Registered Direct OfferingSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Labs Announces $2.5 Million Registered Direct OfferingATLANTA, GA - September 30, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a securities purchase agreement with certain healthcare-focused institutional investors for the purchase and sale of 3,968,256 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 11,904,768 shares of common stock in a registered direct offering (the "Offering") at a combined purchase price of $0.63 per share and accompanying warrant. The warrants will have an exercise price of $0.63 per share, will be exercisable upon shareholder approval and will expire 5 years from shareholder approval.
GeoVax Expands Gedeptin(R) Development to Additional Solid Tumor IndicationsInitiative Builds on Checkpoint Inhibitor Momentum and Landmark KEYNOTE-689 Results
GeoVax Reaffirms Commitment to Evidence-Based Vaccine Safety and Development of GEO-CM04S1 for Vulnerable PopulationsCompany Underscores Rigorous Safety Monitoring and Long History of the MVA Platform as Development of GEO-CM04S1 Advances
GeoVax to Present CM04S1 Clinical Progress at the Emerging Growth ConferenceNext-Generation Multi-Antigen COVID-19 Vaccine Demonstrates Differentiated Immune Responses in Immunocompromised Patients
GeoVax Expands Gedeptin(R) Development to Additional Solid Tumor IndicationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Reaffirms Commitment to Evidence-Based Vaccine Safety and Development of GEO-CM04S1 for Vulnerable PopulationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Present CM04S1 Clinical Progress at the Emerging Growth ConferenceSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Announces Allowance of Patent Protecting Multi-Antigen COVID-19 Vaccine ConstructsExpands Intellectual Property Portfolio Supporting Next-Generation COVID-19 Vaccine Candidates
GeoVax to Present at the Emerging Growth Conference on August 20, 2025Company to Provide Key Updates on GEO-MVA and Its Mpox Vaccine Development Program
GeoVax to Present Multi-Antigen COVID-19 Vaccine Clinical Data at September International Scientific ConferencesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Announces Allowance of Patent Protecting Multi-Antigen COVID-19 Vaccine ConstructsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Present at the Emerging Growth Conference on August 20, 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen VaccineSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
